Keywords: Anthera Pharma, Varespladib, Cardiovascular events, ACS
Anthera tanks as it halts Ph III heart drug trial
Article | 12 March 2012
US development-stage biophama company Anthera Pharmaceuticals (Nasdaq: ANTH) saw its shares plunge as much as 65% to $2.25 in after-hours trading on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
